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Abstract 
Background: Congenital heart disease (CHD) is a common birth defect, and most cases occur sporadically. Muta-
tions in key genes that are responsible for cardiac development could contribute to CHD. To date, the genetic causes 
of CHD remain largely unknown.
Methods: In this study, twenty-nine candidate genes in CHD were sequenced in 106 patients with Tetralogy of 
Fallot (TOF) using target exome sequencing (TES). The co-immunoprecipitation (CO-IP) and luciferase reporter gene 
assays were performed in HEK293T cells, and wild-type and mutant mRNA of ZFPM2 were microinjected into zebrafish 
embryos.
Results: Rare variants in key cardiac transcriptional factors and JAG1 were identified in the patients. Four patients 
carried multiple gene variants. The novel E1148K variant was located at the eighth Zinc-finger domain of FOG2 pro-
tein. The CO-IP assays in the HEK293T cells revealed that the variant significantly damaged the interaction between 
ZFPM2/FOG2 and GATA4. The luciferase reporter gene assays revealed that the E1148K mutant ZFPM2 protein dis-
played a significantly greater inhibition of the transcriptional activation of GATA4 than the wild-type protein. The wild-
type mRNA and the E1148K mutant mRNA of ZFPM2 were injected into zebrafish embryos. At 48 hpf, in the mutant 
mRNA injection group, the number of embryos with an abnormal cardiac chamber structure and a loss of left–right 
asymmetry was increased. By 72 hpf, the defects in the chamber and left–right asymmetry became obvious.
Conclusions: We performed TES in sporadic TOF patients and identified rare variants in candidate genes in CHD. We 
first validated the E1148 K variant in ZFPM2, which is likely involved in the pathogenesis of CHD via GATA4. Moreover, 
our results suggest that TES could be a useful tool for discovering sequence variants in CHD patients.
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Background
Congenital heart disease (CHD), which occurs in approx-
imately 1% of newborns, is the most common birth 
defect worldwide [1]. However, the etiology of CHD 
remains largely unknown. Currently, the prevalence of 
CHD in China has reached approximately 26.6 per 1000 
newborns [2]. Cyanotic CHD was a type of a severe con-
genital disease that threatens newborns’ survival and 
quality of life, and Tetralogy of Fallot (TOF) is the most 
prevalent type [3]. TOF was characterized by the tetrad 
of over-riding aorta, ventricular septal defect, pulmo-
nary valve stenosis and right ventricular hypertrophy. It 
is widely accepted that CHD is a multigenic inheritance 
disease. Cardiac development involves numerous elabo-
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pathway molecules [5, 6] and epigenetic regulators [7] are 
essential for normal cardiac development. Mutations in 
these genes may disturb normal signaling transduction, 
which could lead to CHD [8–10].
NKX, GATA and T-box family members constitute the 
core regulatory network that is responsible for normal 
cardiac morphogenesis and are causative genes in CHDs 
[11, 12]. The GATA family members were characterized 
by two zinc finger domains and transcriptional activation 
domains (TADs). The two TAD domains of GATA4 are 
located at the N- and C-terminal, respectively, different 
from GATA5 or GATA6, which located in N-terminal 
[13–15]. Mutations in GATA4, GATA5 and GATA6 were 
identified in patients with CHD [16–18]. The ZFPM2 
gene encodes the FOG2 protein. FOG2 is a transcrip-
tion regulator of the GATA family members that can not 
only bind with GATA but can also recruit the nucleo-
some remodeling and deacetylation (NuRD) complex to 
moderate the GATA-mediated gene regulation [19, 20]. 
Genetic analysis revealed that mutations in ZFPM2 dis-
rupted the interaction with GATA4 or the NuRD com-
plex, leading to CHD [19, 21–23]. During cardiogenesis, 
the Notch signaling pathway plays significant roles in 
cell fate specification and tissue patterning [24]. Notch 
signaling could also regulate the GATA-dependent car-
diac gene expression [25]. Mutations in elements along 
this pathway result in cardiac malformation [26]. JAG1 
is expressed in the mesocardium, pulmonary artery and 
aorta during embryogenesis [27]. The conditional knock-
out of Jag1 in the cardiac neural crest or endocardium led 
to cardiac defects [28, 29].
In this study, we designed a gene panel, which con-
tained twenty-nine candidate genes in CHD, including 
the key cardiac transcription factors and other cardio-
genesis-related genes. The coding regions of these genes 
were analyzed in 106 patients with TOF using target 
exome sequencing (TES) methods. Rare variants in the 
cardiac transcription factors and Notch signaling path-
way elements were identified. Additionally, a novel vari-
ant in ZFPM2 was selected for a functional study. Our 
results suggest that TES could be a useful tool for discov-




The 106 non-syndromic patients with TOF, who were 
enrolled at the Children’s Hospital of Fudan Univer-
sity, were aged between 1 and 214  months. All patients 
were diagnosed by echocardiography. There were 65 
boys and 41 girls, and the average age is 18.6  months. 
Among the patients, there were 40 cases with only sim-
plex TOF, which accounted for approximately 37.7%. 
There were 38 patients with TOF with PFO or/and PDA, 
which accounted for approximately 35.8%. There were 8 
patients who suffered from TOF with ASD or AVSD, and 
2 patients had TOF with LSVC. The general clinical char-
acteristics of the 106 patients are summarized in Table 1 
and Additional file  1: Table S1. All peripheral venous 
blood samples from the patients used in this study were 
collected with the appropriate informed consent and 
the approval of the ethics committees of the Children’s 
Hospital, Fudan University (2014-107). All genomic 
DNA samples were extracted from whole blood using 
the QIAamp DNA Blood Mini Kit (Qiagen, Germany) 
following the manufacturer’s protocol. The quality and 
quantity of the DNA samples were measured using the 
NanoDrop 2000 spectrophotometer (Thermo Fisher Sci-
entific, USA).
CHD panel design
Twenty-nine genes were included in this CHD panel, 
including key cardiac transcription factors, and structural 
proteins. All genes were reported to have had mutations 
in human CHD patients and were deposited in the human 
genome mutation database (HGMD: http://www.biobase-
international.com/) (Additional file 2: Table S2). The prim-
ers were designed online using life technology (https://www.
ampliseq.com/). The Ampliseq primers were designed to 
cover all exons and at least 10 bp of all intron/splice sites.
Candidate genes sequencing
The ion Torrent PGM™ platform was used for the 
sequencing. The Ampliseq panel library was derived 
from multiple PCR reactions that were conducted 
using the Ion AmpliSeq™ HiFi Mix and Ion AmpliSeq™ 
Table 1 Clinical characteristics of the patients
TOF Tetralogy of Fallot, ASD atrial septum defect, AVSD atrioventricular septum 






Age at diagnosis (months) 18.6 1–216
Diagnosis types of TOF
 TOF 40 38%
 TOF + ASD 6 6%
 TOF + AVSD 2 1%
 TOF + LSVC 2 1%
 TOF + PDA 1 1%
 TOF + PFO 29 28%
 TOF + PDA + PFO 8 8%
 TOF + Others 18 17%
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Primer Pool, in addition to the digestion of the primer 
sequences (Ion AmpliSeq™ Library Kits 2.0), followed 
by adaptor and barcode ligation (Ion Xpress Barcode 
Adapters Kit, Life Technologies, USA). The librar-
ies were quantified using real-time PCR by the IonTaq 
Assay (Ion Library Quantification Kit, Life Technolo-
gies) and diluted to 100  pM. Different patients were 
distinguished by the barcode ligation (Ion Xpress Bar-
code Adapters Kit, Life Technologies, USA). Therefore, 
according to the manufacturers of the kits, we could 
also use Amplicon to add other candidate genes or any 
gap to the same sample using the same barcode in one 
run. We used the Ion OneTouch™ system (Life Tech-
nologies, USA) to clonally amplify the pooled barcoded 
libraries of the Ion Sphere™ particles. Torrent Suite™ 
software was used to compare the base calls. We pooled 
8–12 cases of barcoded sample libraries on one 316™ 
or 316v2™ chip for sequencing. In addition, the aver-
age sequence depth of each case was greater than 400X, 
with 95% over 20X coverage.
In silico analysis
Torrent Suite™ software was used to compare the base 
calls. Then, the licensed NextGENe software (Softgenet-
ics, USA) was used to complete the data analysis. The 
VCF collected from torrent suite were also annotated by 
ANNOVAR and VEP. All SNVs were compared to 1000 
genomes, ExAC and our laboratory’s internal databases. 
We have data for more than 3500 Chinese non-cardiac 
disease cases. In addition, the risk of single-nucleotide 
variations (SNVs) was predicted by the SIFT (http://sift.
jcvi.org/), polyphen 2 (http://genetics.bwh.harvard.edu/
pph2/) and MutationTaster (http://www.mutationtaster.
org/) software. The UCSC website was used to compare 
the human wild-type proteins to orthologs from different 
species.
Sanger sequencing
The candidate SNVs were amplified by the PCR prim-
ers from the genomic DNA and sequenced by Sanger 
sequencing. The forward and reverse primers were 
designed by the program Primer 3.0 online. The PCR 
products were sequenced using the BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, USA) 
with an ABI 3730 Genetic Analyzer. The sequence data 
were analyzed by the Mutation Surveyor Software (Soft-
genetics, USA).
Co‑immunoprecipitation
The coding regions of human ZFPM2 and GATA4 were 
amplified and tagged with a Flag-tag or HA-tag using the 
PCR methods and were then cloned into the mammalian 
expression vector pCDH (Clontech, USA). The mutant 
E1148 K of ZFPM2 was created using the Toyobo KOD-
Plus Mutagenesis Kit (Code No SMK-101) according to 
the manufacturer’s instructions. HEK293T cells were 
transiently co-transfected with the GATA4 and wild-type 
or mutant of ZFPM2 plasmids using the Viafect transfec-
tion agent (Promega, USA). After 48 h of transfection, the 
cells were collected for the experiments. The cell lysates 
were incubated with the HA affinity gel (Biotool, USA) 
overnight at 4 °C. The interactions between GATA4 and 
the wild-type or mutant ZFPM2 protein were detected 
by western blotting. The antibodies used for the western 
blotting were anti-GATA4 (Genetex, USA), anti-FOG2 
(Santa Cruz, USA), anti-Flag (Abmart, China), and anti-
HA (Abmart, China). Three independent experiments 
were performed. The ImageJ software was used for the 
semi-quantitative analysis to acquire a digital number 
for the analysis. GraphPad 5.0 was used for the statistical 
analysis.
Reporter gene assay
The 2600-bp 5′-flanking region of the atrial natriuretic 
factor (ANF) gene was amplified from normal human 
DNA using the following specific primers: ANF-F: 5′ 
CTAGCTAGCAGTGACCTCCATATTA-3′, ANF-R: 5′ 
CCGCTCGAGTGCTGGCGTCGTCAAG-3′. Then, the 
sequence was cloned into the pGL3 basic vector (Pro-
mega, Madison, WI). In the co-transfection experiments, 
500 ng of the pCDNA3-hGATA4 plasmid, 500 ng of the 
wild-type pCDH-hZFPM2 plasmid, 500 ng of the mutant 
pCDH-hZFPM2 plasmid, and 500  ng of the ANF con-
struct were used. pRLRenilla (Promega, Madison, WI) 
was used as a normalized plasmid. HEK293T cells were 
transfected with the plasmids using the Viafect transfec-
tion agent (Promega, Madison, WI). After 48 h of trans-
fection, the luciferase and Renilla luciferase activities 
were measured using the Dual-Glo luciferase assay sys-
tem (Promega, Madison, WI). The activity of the ANF 
promoter is presented as the fold activation of firefly 
luciferase relative to that of Renilla luciferase. The experi-
ments were performed in triplicate.
Zebrafish experiments
The wild-type zebrafish embryos of the Tu and trans-
genic cmlc2 were as follows: eGFP (cardiac myosin light 
chain 2: eGFP reporter) strains were used in this study. 
Adult zebrafish were reared under standard aquacul-
ture conditions at 28.5  °C on a 14/10 h light/dark cycle. 
The embryos were collected after the group mating and 
kept in an embryo medium (17 mM NaCl, 0.2 mM KCl, 
0.18  mM Ca  (NO3)2, 0.12  mM  MgSO4, 1.5  mM HEPES 
buffer pH 7.1–7.3 and 0.6 μM methylene blue).
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Overexpression of human wild‑type and mutant ZFPM2 
mRNA in zebrafish
The human wild-type and mutant ZFPM2 sequences 
were cloned into the pEasy-T vector (Promega, USA). 
The capped and poly(A) tailed mRNA of hZFPM2 and 
its mutant were synthesized in vitro by transcribing with 
T7 RNA polymerase using the mMessageMachine T7 
Ultra Kit (Ambion, Cat #AM1345, USA). The embryos 
of the transgenic cmlc2 were as follows: eGFP was col-
lected for the microinjection at the single-cell stage. The 
experimental groups included the Mut, WT and control 
groups. For the control group, an equal volume of solu-
tion was injected. One hundred embryos were collected 
from each injection group and the control group. The 
purified mRNA of 450 pg was injected into the embryos 
at the single-cell stage. A minimum of three independent 
experiments was performed for the wild-type and mutant 
ZFPM2 mRNA injections.
RNA extraction and quantitative real‑time PCR
The embryos of the transgenic cmlc2 were as follows: 
eGFP and embryos with human wild-type or mutant 
ZFPM2 mRNA injections were collected 48  h post fer-
tilization (hpf). The total RNA was extracted from the 
embryos at 48 hpf using the TRIzol reagent (Invitrogen, 
CA) and converted to cDNA using the PrimeScript RT 
Reagent Kit (Takara Bio, Japan). The RT-PCR reactions 
were performed with the SYBR Premix Ex Taq™ (Takara 
Bio, Japan) on the Roche 480 plus system. The real-time 






zebrafish β-actin-R: 5′- TCACCAACGTAGCTGTCTTTC 
TG-3′. Gene expression was normalized to β-actin and was 
analyzed using the relative quantification method  (2−ΔΔCt). 
Three independent experiments were performed.
Analysis of zebrafish cardiac morphogenesis
All surviving embryos at 48  h post injection were col-
lected from each group by manually stripping the fertili-
zation membrane under the microscope. For each group, 
the cardiac morphogenesis of fifty embryos at 48 h post 
injection was carefully observed. To analyze the heart 
lopping and chamber formation, the size and structure 
of the atrium and ventricle and their positions were com-
pared among the groups under a Leica M205C inverted 
microscope. The number of embryos with cardiac defects 
in each group was counted. A minimum of three inde-
pendent experiments was performed.
Statistical analysis
The statistical analysis was performed using paired two-
tailed Student’s t test (GraphPad Software, San Diego, 
CA) or Mantel–Haenszel Chi square test (Biostatistics 
Services, IUSM).
Results
Variants in multiple genes were found in single patients
Rare variants of key cardiac transcriptional factors 
and JAG1 were identified in the patients, and detailed 
pathogenic prediction information is shown in Table  2. 
Interestingly, there are four patients, who carry multi-
ple gene variants. Patient B393, with an ECHO diagno-
sis of TOF, carried the JAG1(c.3038A>T, p.H1013L) and 
GATA6(c.972C>G, p.H324Q) variants; patient B294, 
with TOF, carried the JAG1(c.2906T>C, p.M969T) and 
GATA5(c.274G>T, p. A92S) variants; and patients B445 
and B548, both of which were diagnosed with TOF 
and PFO, carried two GATA4 variants (c.1220C>A, 
p.P407Q;c.1138G>A, p.V380 M).
Rare variants in the GATA family member genes
Two variants of GATA4 (c.1220C>A, p.P407Q; 
c.1138G>A, p.V380 M) were found in both patients B445 
and B548. These patients were diagnosed with TOF and 
PFO. Variant V380M was located in the second tran-
scription activation TAD domain (TAD2) of GATA4 
(Fig.  1a). P407Q was reported to be pathogenic in the 
human genome mutation database (HGMD) and Clin-
Var. This variant is conserved (Fig.  1a). The frequencies 
of the two variants are approximately 2% in these patients 
(Table 2).
Two novel variants of GATA5 (c. 943T>A, p.S315T and 
c. 274G>T, p.A92S) were identified. The frequencies were 
both approximately 1% (Table  2). They were located in 
the N-terminal and C-terminal of GATA5 in addition to 
the functional domains (Fig. 1b).
As for GATA6, two novel variants (c.331G>A, p.D111N 
and c.972C>G, p.H324Q) were detected. The frequencies 
in this cohort were both approximately 1% (Table 2). Fur-
thermore, the two variants were all located in the TAD 
domains (Fig.  1c). The variant (c.331G>A, p.D111N) is 
more conserved in different species.
The novel variants of ZFPM2 attenuated the transcriptional 
activation of GATA4
Two missense variants (c.3442G>A, p.E1148K; 
c.3014A>G, p.E1005G) of ZFPM2 were identified in 
patient B430 and B546, respectively (Table 2). The novel 
E1148K variant was located at the eighth Zinc-finger 
domain. This variant is conserved in different species 
(Fig. 2a). We speculated that this variant may damage the 
interaction with GATA4. Co-immunoprecipitation assays 
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in HEK293T cells were performed. Interestingly, the 
western blotting results revealed that the variant signifi-
cantly damaged the interaction between the two proteins. 
Based on the semi-quantitative analysis, the interac-
tion between the E1148K mutant ZFPM2/FOG2 with 
GATA4 was decreased by 50% compared to that with 
the wild-type ZFPM2 protein (Fig. 2b). Thus, this result 
prompted us to investigate whether the changes in the 
interaction affect the transcription activity of GATA4 on 
the promoter of the target gene. The luciferase reporter 
gene assays revealed that the wild-type ZFPM2 protein 
could inhibit the transcriptional activation of GATA4 on 
the promoter of ANF. Furthermore, the E1148K mutant 
ZFPM2 protein displayed a significantly greater inhibi-
tion of the transcriptional activation of GATA4 than the 
wild-type protein (Fig. 2c).
The in  vitro study revealed that the novel variants of 
ZFPM2 attenuated the transcription activity of GATA4. 
Then, we attempted to determine whether the variant 
could be deleterious to cardiac development in  vivo. 
Therefore, wild-type mRNA and E1148K mutant mRNA 
of ZFPM2 were injected into zebrafish embryos. At 
48-hpf, in control and wild type mRNA injection groups, 
the chambers of the ventricle and atrium had been 
formed. In the ventral view, the ventricle and atrium were 
located at the left and right sides of the midline, respec-
tively. The cardiac left–right asymmetry is normal. How-
ever, in the mutant mRNA injection group, the number 
of embryos with an abnormal cardiac chamber struc-
ture and left–right asymmetry was increased. Moreo-
ver, the ventricle and atrium were located at the midline 
rather than on the left and right sides, which is similar 
to the phenotypes of heterotaxy (Fig.  2d). Furthermore, 
the ventricle and atrium of a few embryos displayed the 
complete mirror image of normal, which is similar to the 
phenotypes of situs inversus. By 72-hpf, the defects of the 
chamber and left–right asymmetry became obvious. In 
the E1148K mutant mRNA group, 5% of the embryos had 
severe defects, such as eye defects and spinal curvature. 
However, there were no embryos with severe defects in 
the control or wild-type mRNA injection groups. In total, 
in the E1148K mutant mRNA injection group, 56% of the 
embryos showed cardiac defects. However, the embryos 
with cardiac defects accounted for only 6 and 27% in the 
control and wild-type mRNA injection groups, respec-
tively (Fig. 2e). Notably, the expression of nppa (zebrafish 
ANF gene) in the embryos with the wild-type and 
E1148K mutant ZFPM2 overexpression was significantly 
increased compared with that in the control embryos. 
Furthermore, the expression in the E1148K mutant group 
is significantly lower than that in the wild-type group, 
which is consistent with the in vitro result (Fig. 2f ).
Rare variants of JAG1 were identified
Four rare variants of JAG1 were identified in the four 
independent patients as follows: B151: N504S; B393: 
H1013L; B294: M969T; and B431: P269R. The N504S 
variant is located in the EGF repeat domain (Fig. 3). All 
variants of JAG1 were conserved in different species. 
These four patients were diagnosed with TOF. Addition-
ally, patient B294 and B393 also carried GATA family 
member gene mutations.
Other cardiac transcriptional factor variants
In addition, novel variants were detected in the TBX fam-
ily members and CITED2 in three individuals with TOF. 
The variant of TBX2 (c.2139dupG) was found in a patient 
with TOF and AVSD; variant TBX5 (c.409G>T, p.V137L) 
was found in a TOF patient with PDA and PFO; and the 
CITED2 (c.-1AT) variant was found in a patient with 
TOF and PAA (Table  2). These variants are novel, and 
there is no record in ExAC, 1000 genome, or our internal 
database.
Discussion
During the past decade, a number of pathogenic muta-
tions in different genes have been identified in CHD 
by Sanger sequencing of single genes, TES, or whole-
exome sequencing, and new candidate genes and vari-
ants were constantly reported in CHD patients [30–33]. 
In this study, using TES, we designed a twenty-nine gene 
panel to sequence the coding regions of these candidate 
(See figure on previous page.) 
Fig. 1 Variants in the GATA family members. Blue boxes represent the transcription activation domains (TADs), and red boxes indicate the Zinc finger 
domains (ZFN). Sanger sequencing data are displayed, and the variants are shown in the red frames. Alignment of amino acid residues adjacent to 
the variants shows a conservation among different species, including human, mouse, dog and zebrafish. a Human GATA4 protein domain with the 
variants identified in the TOF patients. The GATA4 protein is composed of four functional domains. V380 M is located in the second TAD, and P407Q 
is located near the second TAD. Sanger sequencing data are displayed, and the variants are shown in the red frames. Amino acid in 407 is conserved 
in human, mouse and dog but not in zebrafish. b Human GATA5 protein domain with the variants identified in the TOF patients. GATA5 protein also 
has four functional domains, and the two novel variants are not located in the functional domain. Sanger sequencing data are displayed, and the 
variants are shown in the red frames. c Human GATA6 protein domain with the variants identified in the TOF patients. The GATA6 protein has five 
functional domains, including two TADs, two ZNFs and one nuclear location signal (NLS), which is presented by the yellow box. The variants D111 N 
and H324Q are localized at the TAD1 and TAD2, respectively. The amino acid in 111 is highly conserved in human, mouse, dog and zebrafish
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genes in 106 sporadic TOF patients. We found potential 
pathogenic variants in the GATA family member genes, 
ZFPM2 and the JAG1 gene. In addition, novel variants in 
the TBX family members and CITED2 have been identi-
fied. These results suggest that TES is an efficient method 
for next generation sequencing (NGS) based custom 
designed capture panels.
The GATA family members GATA4, GATA6 and 
GATA5 are reported to be associated with CHD. These 
genes are characterized by transcriptional activation 
domains and zinc-finger domains, which are crucial for 
the transcription of cardiac genes. A deficiency in these 
genes in mice contributed to cardiac abnormalities [34–
36]. Mutations in these genes were identified in patients 
with various types of CHD. In this study, two variants 
were identified in TOF patients. P407Q was identified in 
CHD patients in a previous study [37]. P407Q is recorded 
in HGMD and ClinVar as a pathogenic variant. In addi-
tion, the V380 M variant was identified in a VSD patient 
in a previous study [18]. Moreover, two novel variants 
were identified in the TAD domains of GATA6, both of 
which are novel variants.
In this study, rare variants of ZFPM2 were identified in 
patients B430 and B546. Mutations in ZFPM2 were pre-
viously identified in patients with TOF and DORV [22, 
23]. ZFPM2 (FOG2), which is a transcriptional regula-
tion factor, is reported to show an expression pattern 
that is consistent with that of GATA family members 
in cardiac embryogenesis. Moreover, ZFPM2can inter-
act with the GATA family members via the zinc finger 
domain of GATA to regulate the activities of those mem-
bers [38]. The E1148K variant was novel and predicted 
to be pathogenic. This variant was located at the eighth 
Zinc-finger domain of the ZFPM2 gene, and we specu-
lated that this variant may damage the interaction with 
GATA4. Interestingly, the co-immunoprecipitation assay 
results obtained by western blotting revealed that the 
variant significantly damaged the interaction between 
the ZFPM2 protein and GATA4. During different stages 
of development, FOG2 can combine with GATA4 to 
activate or repress gene expression [39]. The atrial 
natriuretic factor (ANF) was reported to be the target 
gene of GATA4 [40]. The transcription of ANF could 
be activated by GATA4 on the promoter. When FOG2 
combines with GATA4, it can inhibit the transcription 
activation role of GATA4 on the promoter of ANF. How-
ever, FOG2 alone can display a moderate transcription 
activation role on the promoter of ANF [39]. To fur-
ther confirm the effects of this variant, we compared 
the transcription activity of ANF between the wild-type 
ZFPM2 and the E1148K mutant ZFPM2 protein. Nota-
bly, the E1148K mutant ZFPM2 showed a significantly 
greater inhibitory role in the transcriptional activation 
of GATA4. To the best of our knowledge, this is the first 
report to demonstrate that the variant in the eighth zinc 
finger domain of ZFPM2 affects the interaction with 
GATA4 and the transcriptional activation of GATA4. 
Then, zebrafish were used for a functional analysis of this 
variant in  vivo. The overexpression of mutant mRNA 
in zebrafish embryos resulted in cardiac morphologi-
cal abnormalities. Interestingly, embryos that received 
the E1148K mutant mRNA injection displayed an obvi-
ous loss of the left–right asymmetry. Furthermore, we 
found that the overexpression of ZFPM2 could increase 
the expression level of nppa (zebrafish ANF gene) in 
zebrafish. Notably, the expression level of nppa in the 
(See figure on previous page.) 
Fig. 2 The variant of ZFPM2 attenuated the transcriptional activation of GATA4 and contributed to the cardiac abnormalities in zebrafish. a Diagram 
of the human ZFPM2/FOG2 protein domain with the location of its variants identified. The eight zinc-finger motifs (ZNF) are represented by yel-
low boxes. The nuclear localization signal (NLS) is indicated by a green box. The putative CtBP-binding site (CBS) is represented by a pink box. The 
N-terminal transcriptional repression domain (TRD) is indicated by a blue box. E1148 K found in B430 is located at the eighth Zinc-finger domain, 
and E1005G found in B548 is located in the seventh and eighth domains. Sanger sequencing shows the variant in the red frame. Both are conserved 
in human, mouse, dog and zebrafish. The amino acid residue altered by the mutation is shown in the red box. b Co-immunoprecipitation assays in 
HEK293T cells revealed that the E1148 K variant significantly damaged the interaction between ZFPM2 and GATA4 on the western blot. The semi-
quantitative analysis of the western blot results shows that the E1148 K mutant ZFPM2 protein significantly disrupted the interaction with GATA4 
compared to the wild-type ZFPM2 protein. The experiment was repeated three times. (p < 0.05 *, p < 0.01 **) c Luciferase reported gene assays 
were performed. The result revealed that the wild-type ZFPM2 protein could inhibit the transcriptional activation of GATA4 on the promoter of 
ANF. Furthermore, E1148 K inhibited the transcriptional activation of the GATA4 on the ANF promoter significantly more than the WT. Experiments 
were performed in triplicate, and the mean and standard deviations are shown. (*p < 0.05 and **p < 0.01). d Overexpression of the mutant ZFPM2 
protein (E1148 K) contributes to the abnormal cardiac morphogenesis in the zebrafish embryos. In the control and wild-type human ZFPM2 mRNA 
injection groups, the embryos show normal cardiac left–right asymmetry at 48 and 72 hpf. The normal cardiac left–right asymmetry is “left (L)”: the 
ventricle is on the left side of the midline, and the atrium is on the right side. However, in the mutant mRNA injection group, the embryos showed 
the “right (R)” or “straight (S)” abnormal left–right asymmetry. e In each group, the cardiac morphogenesis of fifty embryos (n = 50) was analyzed. 
The number of embryos with cardiac defects, including size, left–right asymmetry, looping and pericardialites, was counted. The proportion of 
embryos with cardiac defects in the mutant human ZFPM2 protein (E1148 K) injection group is significantly higher than that in the other two 
groups. Three independent experiments were performed. (*p < 0.05 and **p < 0.01). f The nppa (zebrafish ANF gene) mRNA level in the embryos 
that received the E1148 K mutant human ZFPM2 mRNA injection is lower than that in the wild-type human ZFPM2 mRNA injection group. The 
mean and standard deviations are shown. Experiments were performed in triplicate. (*p < 0.05 and **p < 0.01)
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embryos that received the mutant mRNA injection is 
significantly lower than that in the embryos that received 
the wild-type mRNA injection, which is consistent with 
the in vitro result. The experiments in the zebrafish pro-
vided strong evidence that the novel variant of ZFPM2 is 
pathogenic in CHD.
Fig. 3 Rare variants of JAG1 identified in patients. Human JAG1 protein structures with the location of the variants identified are shown above the 
diagram. The amino acid positions of the putative JAG1 functional domains are shown below the protein diagram. Blue box represents the signal 
peptide, and the green box indicates the DSL domain. In addition, the dark blue boxes show the EGF repeat domains, and the orange box represents 
the transmembrane domain. Four variants (p.P269R, p.N504S, p. M969T, p. H1013L) of JAG1 were identified and were conservative in different 
species, including human, mouse, dog and zebrafish. The amino acid residue altered by the mutation is shown in the red frame. All variants were 
confirmed by Sanger sequencing and are shown in the red frames. The variant p. N504S is located on the EGF repeats domain, and the other three 
variants are not in the functional domain
Page 11 of 14Qian et al. J Transl Med  (2017) 15:69 
Intriguingly, multiple gene variants in JAG1 and the 
GATA family members were detected. JAG1 is a recep-
tor of NOTCH1, which could help the transportation of 
NOTCH1 to activate the genes that are downstream in 
the Notch signaling pathway [41]. Heterozygous muta-
tions in JAG1 contributed to the pathogenesis of Alagille 
syndrome (AGS) [42], TOF, and peripheral pulmonary 
stenosis (PPS) [10]. However, heterozygous Jag1 mutant 
mice only showed an eye defect [43]. However, for mice 
that were compound heterozygous for the Jag1 null 
allele and a Notch2 hypomorphic allele showed defects 
that were similar to AGS, including cardiac defects [44]. 
These results suggested that the pathogenesis of CHD 
may involve multiple gene deficiencies. HEY transcrip-
tional factors, which are activated by NOTCH signal-
ing, could repress gene expression [45]. Previous studies 
showed that HEY proteins can not only interact with 
the GATA family members at the GATA binding DNA 
element but can also regulate the transcriptional activ-
ity of GATA to repress the downstream genes, such as 
ANF [25]. It was suggested that the interaction between 
NOTCH signaling and the GATA family members is 
indispensable for cardiac development. Therefore, in 
patients B393 and B294, it is likely that the accumulation 
Fig. 4 Two possible genetic etiologies of CHD. a Monogenic mutations in a key cardiac regulator may be the cause of CHD. A pathogenic E1148 K 
variant of ZFPM2 in patient B430 decreased the binding of ZFPM2 and GATA4 and attenuated the transcriptional activation of GATA4 on the pro-
moter of ANF. b The majority of the variants in the GATA family member genes and JAG1 occurred sporadically in the patients. However, patients 
B294 and B393 carried two variants in two genes. B393 carried one variant in JAG1 and one variant in GATA6 variant, shown in a blue color, and B294 
carried one variant in JAG1 and one variant in GATA5, shown in a green color. The results support the notion that rare, moderate-effect gene variants 
occur simultaneously in patients and may increase the susceptibility to cardiac malformations. The interaction between NOTCH signaling and the 
GATA family members is indispensable for cardiac development
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of multiple gene variations could cooperatively contrib-
ute to the pathogenesis of CHD, and the heterogeneity of 
the CHD subtype may be related to the different genetic 
deficiency patterns. As described in Fig. 4, we speculate 
that the variants of JAG1 likely attenuated the transcrip-
tional activation of HEY proteins via an abnormal sign-
aling transduction and then affected the transcriptional 
regulation of the GATA family members, which might 
have an additive effect for the variants in these members.
The TBX transcription factors share a highly conserved 
DNA-binding domain, play vital roles in embryonic 
development and are required for cardiac morphogen-
esis in mammals [46]. A novel c.2139dupG variant in 
TBX2 was found in a patient with TOF and AVSD. The 
TBX2 gene is expressed in myocardiac tissue and the out-
flow tract and plays a vital role in heart chamber forma-
tion. Genomic deletions and duplications of the TBX2 
gene have been associated with cardiac defects [47]. The 
variant of TBX5 (c. 409G>T, p. V137L) is located at the 
T-Box domain, which likely affects the function of TBX5.
Conclusions
In summary, we identified rare variants in cardiac tran-
scription factors and JAG1 in sporadic patients with 
TOF. Notably, a novel pathogenic variant of ZFPM2 was 
proven to attenuate the interaction between ZFPM2 
with GATA4 and inhibit the transcription activity of 
GATA4. In addition, the overexpression of E1148  K 
mutant mRNA in zebrafish embryos resulted in cardiac 
malformation in the zebrafish. Furthermore, variants in 
the GATA family member genes and JAG1 were identi-
fied. This result suggested that multiple gene deficiencies 
could contribute to the pathogenesis of CHD. We believe 
that with the development of genetic modification tools, 
such as the CRISPR-Cas9 system, which could provide 
more support for single-gene or multigene functional 
studies, better knowledge regarding the genetic etiology 
of CHD will be established in the future.
Abbreviations
CHD: congenital heart diseases; TOF: Tetralogy of Fallot; OMIM: online 
mendelian inheritance; NGS: next-generation sequencing; WES: whole 
exome sequencing; TAD: transcriptional activation domains; NuRD: nucleo-
some remodeling and deacetylation; TES: target exome sequencing; SNVs: 
single-nucleotide variations; ANF: atrial natriuretic factor; cmlc2: eGFP: cardiac 
myosin light chain 2:eGFP reporter; hpf: hour post fertilization; HGMD: human 
genome mutation database; AGS: Alagille syndrome; PPS: peripheral pulmo-
nary stenosis; PDA: patent ductus arteriosus; PFO: patent foramen ovale; PAA: 
pulmonary artery absent.
Additional files
Additional file 1: Table S1. Patients’ clinical characteristics.
Additional file 2: Table S2. Information of twenty-nine candidate genes.
Authors’ contributions
YQ and HW conceived and designed the study. XM and GH collected the 
study data. YQ and XG performed the genetic analyses. DX and XG performed 
the functional study. HC and LH help complete the construction of the 
plasmids. YQ and DX drafted the manuscript. HW and DM finalized the manu-
script. All authors read and approved the final manuscript.
Author details
1 Key Laboratory of Metabolism and Molecular Medicine, Ministry of Edu-
cation, Department of Biochemistry and Molecular Biology, Collaborative 
Innovation Center of Genetics and Development, Institutes of Biomedical 
Sciences, School of Basic Medical Sciences, Fudan University, Shanghai 20032, 
China. 2 Shanghai Key Lab of Birth Defect, Children’s Hospital of Fudan Uni-
versity, Shanghai 201102, China. 3 Pediatric Heart Center, Children’s Hospital 
of Fudan University, Shanghai 201102, China. 4 Research Center for Birth 
Defects, School of Basic Medical Sciences, Fudan University, 130 Dongan Road, 
Shanghai 200030, China. 5 Molecular Genetics Laboratory, Children’s Hospital 
of Fudan University, 399 Wanyuan Road, Shanghai 201102, China. 
Acknowledgements
The authors are grateful to the patients involved in the study. We thank the 
teams of the Molecular Genetic Laboratory, Children’s Hospital of Fudan Uni-
versity, for their support with the Next Generation Sequencing in this study. 
This work was supported by the National Natural Science Foundation of China 
(NSFC: 81471483 and NSFC: 81570286) and the National Key Research and 
Development Program (2016YFC1000500).
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analyzed in this study are included in this published 
article and its supplementary information files.
Ethical approval and consent to participate
The study protocols were reviewed and approved by the Institutional 
Research Ethics Committee of the Children’s Hospital of Fudan University 
(2016-56). The blood samples used in this study were collected with appropri-
ate informed consent. The samples from patients and zebrafish were used 
with the approval of the ethics committees of the Children’s Hospital, Fudan 
University (2014-107).
Funding
This work was funded by the National Natural Science Foundation of China 
(NSFC: 81471483 and NSFC: 81570286) and the National Key Research and 
Development Program (2016YFC1000500).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 13 October 2016   Accepted: 23 March 2017
References
 1. Pierpont ME, Basson CT, Benson DW Jr, Gelb BD, Giglia TM, Gold-
muntz E, McGee G, Sable CA, Srivastava D, Webb CL. American Heart 
Association Congenital Cardiac Defects Committee CoCDitY: genetic 
basis for congenital heart defects: current knowledge: a scientific 
statement from the American Heart Association Congenital Cardiac 
Defects Committee, Council on Cardiovascular Disease in the Young: 
endorsed by the American Academy of Pediatrics. Circulation. 
2007;115:3015–38.
 2. Zhao QM, Ma XJ, Jia B, Huang GY. Prevalence of congenital heart disease 
at live birth: an accurate assessment by echocardiographic screening. 
Acta Paediatr. 2013;102:397–402.
Page 13 of 14Qian et al. J Transl Med  (2017) 15:69 
 3. Grunert M, Dorn C, Schueler M, Dunkel I, Schlesinger J, Mebus S, Alexi-
Meskishvili V, Perrot A, Wassilew K, Timmermann B, et al. Rare and private 
variations in neural crest, apoptosis and sarcomere genes define the 
polygenic background of isolated Tetralogy of Fallot. Hum Mol Genet. 
2014;23:3115–28.
 4. McCulley DJ, Black BL. Transcription factor pathways and congenital heart 
disease. Curr Top Dev Biol. 2012;100:253–77.
 5. Ruiz-Villalba A, Hoppler S, van den Hoff MJ. Wnt signaling in the heart 
fields: variations on a common theme. Dev Dyn. 2016;245:294–306.
 6. Luxan G, D’Amato G, MacGrogan D, de la Pompa JL. Endocardial notch 
signaling in cardiac development and disease. Circ Res. 2016;118:e1–18.
 7. Bevilacqua A, Willis MS, Bultman SJ. SWI/SNF chromatin-remodeling com-
plexes in cardiovascular development and disease. Cardiovasc Pathol. 
2014;23:85–91.
 8. Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CA, 
Rothrock CR, Eapen RS, Hirayama-Yamada K, Joo K, et al. GATA4 mutations 
cause human congenital heart defects and reveal an interaction with 
TBX5. Nature. 2003;424:443–7.
 9. Wang J, Lu Y, Chen H, Yin M, Yu T, Fu Q. Investigation of somatic NKX2-5, 
GATA4 and HAND1 mutations in patients with Tetralogy of Fallot. Pathol-
ogy. 2011;43:322–6.
 10. Bauer RC, Laney AO, Smith R, Gerfen J, Morrissette JJ, Woyciechowski 
S, Garbarini J, Loomes KM, Krantz ID, Urban Z, et al. Jagged1 (JAG1) 
mutations in patients with Tetralogy of Fallot or pulmonic stenosis. Hum 
Mutat. 2010;31:594–601.
 11. Srivastava D. Genetic regulation of cardiogenesis and congenital heart 
disease. Annu Rev Pathol. 2006;1:199–213.
 12. Su W, Zhu P, Wang R, Wu Q, Wang M, Zhang X, Mei L, Tang J, Kumar M, Wang 
X, et al. Congenital heart diseases and their association with the variant 
distribution features on susceptibility genes. Clin Genet. 2017;91:349–54.
 13. Sumi K, Tanaka T, Uchida A, Magoori K, Urashima Y, Ohashi R, Ohguchi 
H, Okamura M, Kudo H, Daigo K, et al. Cooperative interaction between 
hepatocyte nuclear factor 4 alpha and GATA transcription factors regu-
lates ATP-binding cassette sterol transporters ABCG5 and ABCG8. Mol Cell 
Biol. 2007;27:4248–60.
 14. Gallagher JM, Yamak A, Kirilenko P, Black S, Bochtler M, Lefebvre C, 
Nemer M, Latinkic BV. Carboxy terminus of GATA4 transcription factor is 
required for its cardiogenic activity and interaction with CDK4. Mech Dev. 
2014;134:31–41.
 15. Prendiville T, Jay PY, Pu WT. Insights into the genetic structure of con-
genital heart disease from human and murine studies on monogenic 
disorders. Cold Spring Harb Perspect Med. 2014;4:a013946.
 16. Kodo K, Nishizawa T, Furutani M, Arai S, Yamamura E, Joo K, Takahashi T, 
Matsuoka R, Yamagishi H. GATA6 mutations cause human cardiac outflow 
tract defects by disrupting semaphorin-plexin signaling. Proc Natl Acad 
Sci USA. 2009;106:13933–8.
 17. Jiang JQ, Li RG, Wang J, Liu XY, Xu YJ, Fang WY, Chen XZ, Zhang W, Wang 
XZ, Yang YQ. Prevalence and spectrum of GATA5 mutations associated 
with congenital heart disease. Int J Cardiol. 2013;165:570–3.
 18. Granados-Riveron JT, Pope M, Bu’lock FA, Thornborough C, Eason J, 
Setchfield K, Ketley A, Kirk EP, Fatkin D, Feneley MP, et al. Combined muta-
tion screening of NKX2-5, GATA4, and TBX5 in congenital heart disease: 
multiple heterozygosity and novel mutations. Congenit Heart Dis. 
2012;7:151–9.
 19. Garnatz AS, Gao Z, Broman M, Martens S, Earley JU, Svensson EC. FOG-2 
mediated recruitment of the NuRD complex regulates cardiomyocyte 
proliferation during heart development. Dev Biol. 2014;395:50–61.
 20. Crispino JD, Lodish MB, Thurberg BL, Litovsky SH, Collins T, Molkentin JD, 
Orkin SH. Proper coronary vascular development and heart morphogen-
esis depend on interaction of GATA-4 with FOG cofactors. Genes Dev. 
2001;15:839–44.
 21. Pizzuti A, Sarkozy A, Newton AL, Conti E, Flex E, Digilio MC, Amati F, Gianni 
D, Tandoi C, Marino B, et al. Mutations of ZFPM2/FOG2 gene in sporadic 
cases of Tetralogy of Fallot. Hum Mutat. 2003;22:372–7.
 22. De Luca A, Sarkozy A, Ferese R, Consoli F, Lepri F, Dentici ML, Vergara P, 
De Zorzi A, Versacci P, Digilio MC, et al. New mutations in ZFPM2/FOG2 
gene in Tetralogy of Fallot and double outlet right ventricle. Clin Genet. 
2011;80:184–90.
 23. Tan ZP, Huang C, Xu ZB, Yang JF, Yang YF. Novel ZFPM2/FOG2 variants in 
patients with double outlet right ventricle. Clin Genet. 2012;82:466–71.
 24. Luna-Zurita L, Prados B, Grego-Bessa J, Luxan G, del Monte G, Bengu-
ria A, Adams RH, Perez-Pomares JM, de la Pompa JL. Integration of a 
notch-dependent mesenchymal gene program and Bmp2-driven cell 
invasiveness regulates murine cardiac valve formation. J Clin Invest. 
2010;120:3493–507.
 25. Fischer A, Klattig J, Kneitz B, Diez H, Maier M, Holtmann B, Englert C, 
Gessler M. Hey basic helix-loop-helix transcription factors are repressors 
of GATA4 and GATA6 and restrict expression of the GATA target gene ANF 
in fetal hearts. Mol Cell Biol. 2005;25:8960–70.
 26. Fischer A, Klamt B, Schumacher N, Glaeser C, Hansmann I, Fenge H, 
Gessler M. Phenotypic variability in Hey2 −/− mice and absence of HEY2 
mutations in patients with congenital heart defects or Alagille syndrome. 
Mamm Genome. 2004;15:711–6.
 27. Jones EA, Clement-Jones M, Wilson DI. JAGGED1 expression in human 
embryos: correlation with the Alagille syndrome phenotype. J Med 
Genet. 2000;37:658–62.
 28. High FA, Jain R, Stoller JZ, Antonucci NB, Lu MM, Loomes KM, Kaestner 
KH, Pear WS, Epstein JA. Murine Jagged1/Notch signaling in the second 
heart field orchestrates Fgf8 expression and tissue-tissue interactions 
during outflow tract development. J Clin Invest. 2009;119:1986–96.
 29. Hofmann JJ, Briot A, Enciso J, Zovein AC, Ren S, Zhang ZW, Radtke F, 
Simons M, Wang Y, Iruela-Arispe ML. Endothelial deletion of murine Jag1 
leads to valve calcification and congenital heart defects associated with 
Alagille syndrome. Development. 2012;139:4449–60.
 30. Jia Y, Louw JJ, Breckpot J, Callewaert B, Barrea C, Sznajer Y, Gewillig M, 
Souche E, Dehaspe L, Vermeesch JR, et al. The diagnostic value of next 
generation sequencing in familial nonsyndromic congenital heart 
defects. Am J Med Genet A. 2015;167A:1822–9.
 31. Blue GM, Kirk EP, Giannoulatou E, Dunwoodie SL, Ho JW, Hilton DC, White 
SM, Sholler GF, Harvey RP, Winlaw DS. Targeted next-generation sequenc-
ing identifies pathogenic variants in familial congenital heart disease. J 
Am Coll Cardiol. 2014;64:2498–506.
 32. Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ, DePalma SR, 
McKean D, Wakimoto H, Gorham J, et al. De novo mutations in congenital 
heart disease with neurodevelopmental and other congenital anomalies. 
Science. 2015;350:1262–6.
 33. Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, Romano-
Adesman A, Bjornson RD, Breitbart RE, Brown KK, et al. De novo muta-
tions in histone-modifying genes in congenital heart disease. Nature. 
2013;498:220–3.
 34. Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM, Parmacek MS, 
Soudais C, Leiden JM. GATA4 transcription factor is required for ventral 
morphogenesis and heart tube formation. Genes Dev. 1997;11:1048–60.
 35. Morrisey EE, Tang Z, Sigrist K, Lu MM, Jiang F, Ip HS, Parmacek MS. GATA6 
regulates HNF4 and is required for differentiation of visceral endoderm in 
the mouse embryo. Genes Dev. 1998;12:3579–90.
 36. Laforest B, Andelfinger G, Nemer M. Loss of Gata5 in mice leads to bicus-
pid aortic valve. J Clin Invest. 2011;121:2876–87.
 37. Zhang W, Li X, Shen A, Jiao W, Guan X, Li Z. GATA4 mutations in 486 
Chinese patients with congenital heart disease. Eur J Med Genet. 
2008;51:527–35.
 38. Tevosian SG, Deconinck AE, Cantor AB, Rieff HI, Fujiwara Y, Corfas G, 
Orkin SH. FOG-2: a novel GATA-family cofactor related to multitype zinc-
finger proteins friend of GATA-1 and U-shaped. Proc Natl Acad Sci USA. 
1999;96:950–5.
 39. Lu JR, McKinsey TA, Xu H, Wang DZ, Richardson JA, Olson EN. FOG-2, a 
heart- and brain-enriched cofactor for GATA transcription factors. Mol Cell 
Biol. 1999;19:4495–502.
 40. Grepin C, Dagnino L, Robitaille L, Haberstroh L, Antakly T, Nemer M. A 
hormone-encoding gene identifies a pathway for cardiac but not skeletal 
muscle gene transcription. Mol Cell Biol. 1994;14:3115–29.
 41. Shimizu K, Chiba S, Saito T, Kumano K, Hirai H. Physical interaction of 
Delta1, Jagged1, and Jagged2 with Notch1 and Notch3 receptors. Bio-
chem Biophys Res Commun. 2000;276:385–9.
 42. Warthen DM, Moore EC, Kamath BM, Morrissette JJ, Sanchez-Lara 
PA, Piccoli DA, Krantz ID, Spinner NB. Jagged1 (JAG1) mutations in 
Alagille syndrome: increasing the mutation detection rate. Hum Mutat. 
2006;27:436–43.
 43. Xue Y, Gao X, Lindsell CE, Norton CR, Chang B, Hicks C, Gendron-Maguire 
M, Rand EB, Weinmaster G, Gridley T. Embryonic lethality and vascular 
Page 14 of 14Qian et al. J Transl Med  (2017) 15:69 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
defects in mice lacking the Notch ligand Jagged1. Hum Mol Genet. 
1999;8:723–30.
 44. McCright B, Lozier J, Gridley T. A mouse model of Alagille syndrome: 
Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development. 
2002;129:1075–82.
 45. Xiang F, Sakata Y, Cui L, Youngblood JM, Nakagami H, Liao JK, Liao R, Chin 
MT. Transcription factor CHF1/Hey2 suppresses cardiac hypertrophy 
through an inhibitory interaction with GATA4. Am J Physiol Heart Circ 
Physiol. 2006;290:H1997–2006.
 46. Greulich F, Rudat C, Kispert A. Mechanisms of T-box gene function in the 
developing heart. Cardiovasc Res. 2011;91:212–22.
 47. Pang S, Liu Y, Zhao Z, Huang W, Chen D, Yan B. Novel and functional 
sequence variants within the TBX2 gene promoter in ventricular septal 
defects. Biochimie. 2013;95:1807–9.
